Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.
Cellvie has raised $5.0M in total funding. The most recent round was Seed. The last funding was announced in September 2025.
Cellvie's investors include Innosuisse, Taiho Ventures, Beiersdorf, KIZOO Technology Capital.
Cellvie is headquartered in Houston, United States.
Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.
Cellvie is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cellvie — Funding & Investors." VCBacked, September 9, 2025, https://www.vcbacked.co/company/cellvie. Accessed August 1, 2026.
VCBacked. (2025). Cellvie — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/cellvie
{{cite web |title=Cellvie — Funding & Investors |url=https://www.vcbacked.co/company/cellvie |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated